The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > November 6, 2025
Daily News
November 6, 2025
- Keytruda Faces 5th Price Cut under Special Re-Pricing; MSD Warns of Ripple Effects
November 6, 2025
- Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen
November 6, 2025
- MOF Floats New Patient Cost Scheme, Eyes Revival of Old Copay System
November 6, 2025
- Reblozyl to Face 8% Cut, Vyloy 4% in February: CEA Adjustment
November 6, 2025
- Servier’s Voranigo Skips November Listing; GSK, BMS Drugs Also Absent
November 6, 2025
- Tepid Exchanges at Chuikyo over Public-Private Working Group Report
November 6, 2025
- Takaichi Pledges Balanced Approach to Drug Pricing, Off-Year Revisions
November 6, 2025
- Leqembi Sales Soar 153% in H1 FY2025; Eisai Pins Hopes on Self-Injector, Blood Tests
November 6, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…